Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003
Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004
Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005
Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Surgical treatment of destructive pulmonary tuberculosis (TB) with multi-drug resistance (MDR) Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Drug resistance of Mycobacterium tuberculosis to fluoroquinolones (Q) Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003
Short course of chemotherapy of multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Prevalence of relevant multi-drug resistant (MDR) pathogens in a bronchiectasis (BE) cohort. Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019
Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB. Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Surgical treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Multidrug resistant pulmonary TB: Characteristics of drug resistance profiles of MBT in Ukraine Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Regional reference centre for multi-drug resistant tuberculosis – 11 months of activity Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011